• Community News
  • Medical and Scientific News
  • Features
Canadian Hemophilia Society
  • Français
chsLogo
  • Community News
  • Medical and Scientific News
  • Features
Home / Articles posted by Kathy Lawday
  • Management of comorbidities in bleeding disorders

    By Kathy Lawday on August 12, 2020

    Three decades of people with hemophilia unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, has again...

  • Substitution therapy

    By Kathy Lawday on August 12, 2020

    Hemlibra (emicizumab) is indicated in Canada for hemophilia A patients with or without factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the...

  • Inhibitors – think differently

    By Kathy Lawday on July 23, 2020

    The development of inhibitory antibodies to therapeutic FVIII in up to 40% of severe hemophilia A (HA) patients is a major complication in the treatment...

  • The WFH Gene Therapy and Bleeding Disorders Registries

    By Kathy Lawday on July 22, 2020

    WFH Gene Therapy Registry, presented by Dr. Barbara Konkle For many years gene therapy has been in the future – but now, for an increasing...

  • Critical need for harmonized post-marketing surveillance in gene therapy

    By Kathy Lawday on July 13, 2020

    With regulatory approval of the first gene therapy for clinical use outside of clinical trials anticipated in mid-2020, there is an urgent need to collect...

Page 1 of 212
  • KEYWORDS

    ADVOCACY ageing A GLOBAL PERSPECTIVE AIDS CARRIERS COMPENSATION COVID-19 EMICIZUMAB GENE THERAPY HALF-LIFE FACTOR CONCENTRATES HEMLIBRA HEMOPHILIA A AND B HEPATITIS C HIV ICHIP INHIBITORS MYCBDR NURSING PHYSIOTHERAPY Platelet function disorders PROBE PROPHYLAXIS RARE BLEEDING DISORDERS RESEARCH SOCIAL WORK THE BLOOD FACTOR THE FEMALE FACTOR THERAPIES THE SAGE PAGE TWINNING VON WILLEBRAND DISEASE

Copyright © 2020 - Canadian Hemophilia Society. All rights reserved.

  • ARCHIVED HEMOPHILIA TODAY
  • ABOUT US